Ejima Keisuke, Wang Yuqian, Endo Akira, Murayama Hiroaki, Goh Yun Shan, Cook Alex R, Jeong Yong Dam, Iwami Shingo, Park Hyeongki, Dickens Borame Sue Lee, Jin Shihui, Lim Jue Tao, Chan Conrad En Zuo, Chia Po Ying, Young Barnaby E, Yang Yang, Chio Martin, Lye David Chien, Ajelli Marco
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
National Centre for Infectious Diseases, Singapore, Singapore.
BMC Med. 2025 Aug 12;23(1):473. doi: 10.1186/s12916-025-04286-6.
In August 2024, the World Health Organization (WHO) declared a public health emergency due to the rapid spread of mpox in Africa and beyond. International travel controls (ITCs), such as health screening and viral testing, could help avoid/delay the global spread of MPXV, fostering preparedness and response efforts. However, it is not clear whether the viral tests at immigration are sufficient to avoid introduction of MPXV and which samples should be used on the viral tests.
We conducted a simulation study using epidemiological and viral load data to assess the effectiveness of health screening and polymerase chain reaction (PCR) testing at immigration. The primary outcome was the proportion of MPXV-infected travelers identified under various international travel control policies. To estimate time-varying false-negative rates of PCR tests with different detection limits, we employed viral dynamics models calibrated to data from three anatomical sites: oropharynx, saliva, and rectum. Additionally, we simulated the effects of these control measures on the recommended duration of a post-entry monitoring period. Travelers were assumed to depart from mpox-affected countries, defined as those with ongoing MPXV transmission, potentially representing both historically endemic regions and countries with recent outbreaks.
Our results show that under an endemic scenario, the combination of health screening and PCR testing using saliva swabs identifies approximately 74% of MPXV-infected travelers. Using rectal swabs slightly improves detection, identifying up to 79% of infected individuals. A comparable improvement can also be achieved by increasing test sensitivity (i.e., reducing the detection limit from 250 to 10 copies/mL). Based on the distribution of post-entry incubation periods, we estimated that travelers from mpox-affected regions should self-monitor and adopt precautionary behavior for at least 16 days to mitigate the risk of onward transmission.
Health screening and PCR testing at immigration are likely to miss a significant proportion of MPXV-infected travelers, thus a lengthy quarantine period would be required to prevent onward local transmission. Careful consideration on other factors such as economic costs and likelihood of widespread local outbreak will need to be weighed against the adoption of these measures to prevent local mpox transmission given MPXV transmissibility and severity.
2024年8月,世界卫生组织(WHO)宣布由于猴痘在非洲及其他地区的迅速传播而构成公共卫生紧急事件。国际旅行管控措施(ITCs),如健康筛查和病毒检测,有助于避免/延缓猴痘病毒(MPXV)的全球传播,促进防范和应对工作。然而,尚不清楚入境时的病毒检测是否足以避免猴痘病毒的传入,以及病毒检测应使用哪些样本。
我们利用流行病学和病毒载量数据进行了一项模拟研究,以评估入境时健康筛查和聚合酶链反应(PCR)检测的有效性。主要结果是在各种国际旅行管控政策下识别出的感染猴痘病毒的旅行者比例。为了估计不同检测限的PCR检测随时间变化的假阴性率,我们采用了根据来自三个解剖部位(口咽、唾液和直肠)的数据校准的病毒动力学模型。此外,我们模拟了这些管控措施对建议的入境后监测期时长的影响。旅行者被假定来自受猴痘影响的国家,即那些有猴痘病毒持续传播的国家,可能既包括历史上的流行地区,也包括近期爆发疫情的国家。
我们的结果表明,在地方流行的情况下,结合健康筛查和使用唾液拭子进行PCR检测可识别出约74%感染猴痘病毒的旅行者。使用直肠拭子可略微提高检测率,识别出高达79%的感染者。通过提高检测灵敏度(即把检测限从250拷贝/毫升降至10拷贝/毫升)也能实现类似的改善。根据入境后潜伏期的分布情况,我们估计来自受猴痘影响地区的旅行者应自我监测并采取预防措施至少16天,以降低病毒进一步传播的风险。
入境时的健康筛查和PCR检测很可能会遗漏相当比例感染猴痘病毒的旅行者,因此需要较长的隔离期来防止病毒在当地进一步传播。鉴于猴痘病毒的传播性和严重性,在采取这些措施以预防当地猴痘传播时,需要仔细权衡经济成本和当地广泛爆发疫情的可能性等其他因素。